Identification of ATIC as a Novel Target for Chemoradiosensitization

• Published in: International journal of radiation oncology, biology, physics Vol. 100; no. 1; pp. 162 - 173
• Main Authors: Liu, Xiangfei, Paila, Uma Devi, Teraoka, Sharon N., Wright, Jocyndra A., Huang, Xin, Quinlan, Aaron R., Gatti, Richard A., Concannon, Patrick
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2018
• Subjects: Adenosine Triphosphate - administration & dosage; Cell Cycle Checkpoints - physiology; Cell Line, Tumor; Cell Survival - genetics; Chemoradiotherapy; Comet Assay; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Enzyme Inhibitors - therapeutic use; ENZYMES; Frameshift Mutation; Gene Knockdown Techniques; Histones - analysis; Humans; Hydroxymethyl and Formyl Transferases - antagonists & inhibitors; Hydroxymethyl and Formyl Transferases - deficiency; Hydroxymethyl and Formyl Transferases - genetics; Molecular Targeted Therapy - methods; Multienzyme Complexes - antagonists & inhibitors; Multienzyme Complexes - deficiency; Multienzyme Complexes - genetics; MUTATIONS; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - deficiency; Neoplasm Proteins - genetics; Nucleotide Deaminases - antagonists & inhibitors; Nucleotide Deaminases - deficiency; Nucleotide Deaminases - genetics; PURINES; Radiation-Sensitizing Agents - therapeutic use; RADIOLOGY AND NUCLEAR MEDICINE; RADIOSENSITIVITY; Tumor Stem Cell Assay

Mutations in the gene encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a bifunctional enzyme that catalyzes the final 2 steps of the purine de novo biosynthetic pathway, were identified in a subject referred for radiation sensitivity testing. Functi...